Collaborating in more than 150 countries.By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com.These sections or websites are governed by their own Legal and Privacy Policies.
Asia Pacific (Regional)
English | Français | Nederlands
Deutsch | Français
Central America and the Caribbean
Spanish | English
English | Français
Welcome to Janssen Belgium
Visit Janssen Global
Research & Development at Janssen: innovations which lead to better insights into diseases As far as Janssen is...
Janssen helps to shape the research landscape by investing in outstanding research competencies in the areas of genome...
Janssen Research & Development's three new research platforms focus on disease prevention, disease interception,...
It is estimated that over 2,000 Belgians are confronted for the first time with psychosis susceptibility each year...
Janssen's Clinical Pharmacology Unit (CPU) at the Jan Palfijn hospital in Merksem tests medicines, which are still in...
Many neuropsychiatric complaints are amongst the most destructive and complex illnesses. Our mission is to tackle this...
Janssen is exploring innovative applications of our HIV medicines to improve the treatment and prevention in areas...
Cancer is a very complicated disease and poses a major challenge. However, research into cancer is progressing rapidly...
IBD (Inflammatory Bowel Disease) is a collective name for chronic intestinal diseases , of which Crohn’s disease and...
About 400 million people worldwide are infected with hepatitis B or C. The World Health Organization (WHO) describes...
Janssen has a long tradition of research into mental illness. For more than 50 years, our unwavering commitment to...
In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Actelion,...
The outlook for patients with leukemia and other life-threatening blood cancers* is far more promising than just a...